Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y=SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Abstract: A receiver device includes a first mixer for production of a first analogue intermediate signal by down-mixing of a radio-frequency signal. The device also includes an A/D converter for production of a first digital intermediate signal, a second mixer for production of a second digital intermediate signal from the first digital intermediate signal, and a third mixer for production of a digital baseband signal from the second digital intermediate signal. The second mixer has a higher sampling frequency than the third mixer.

Abstract: A device for scaling and quantization of digital soft output values (sk) from an equalizer has a control loop for controlling a statistical parameter (?) for the scaled and quantized soft output values (sD,k), which contains a calculation unit (4) for calculation of the statistical parameter (?), and a control unit (5) for calculation of a scaling factor (c) for scaling the soft output values (sk) from the equalizer on the basis of the statistical parameter (?).

Abstract: A process for the production of 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones, especially 4-(4-pyridylmethyl)-1(2H)-phthalazinone, is described, which is characterized by the reaction of phthalidyl-3-triphenylphosphonium salt with 4-pyridine aldehyde in the presence of a basic adjuvant, subsequent reaction with hydrazine hydrate and subsequent acid treatment, whereby this process avoids the technical safety and environmental problems of the known processes.

Abstract: In order to compensate for a frequency offset or a change in the phase of the transmission channel over time during mobile radio transmission of data symbols, the data symbols are transmitted by means of carrier-frequency, modulated data bursts. Sample values of the received signal, which are known in advance and correspond to first and second symbols, are evaluated in order to estimate the frequency offset or the change in the phase of the transmission channel over time. These first and second symbols are transmitted with a defined phase angle by means of the data burst, and are arranged separated from one another in the data burst. Edge symbols in a data burst are advantageously used as first and second symbols, or as a symbol pair, for estimation.

Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Abstract: A method for equalization of a signal is provided, wherein the equalization is of a signal that is transmitted via a data channel based on the DF method. The method takes account of at least one interference channel, and includes processing of at least two trellis diagrams in each time unit, with the states of at least one of the trellis diagrams describing the data channel. A DF contribution that is used for processing of this trellis diagram includes information about at least one interference channel.

Abstract: A method of identifying a compound that modulates the activity of a cellular regulator is provided. The method consists of contacting a sample containing a cellular regulator and a nucleic acid element acted on by the cellular regulator with a test compound under conditions that allow replication or expression of the nucleic acid element or a gene or MRNA operatively linked to the nucleic acid element or gene, and an increase or decrease in the amount of replication or expression in the presence of the test compound compared to the absence of the test compound indicates that the compound has cellular regulator modulatory activity. A method of treating a HCV infection is also provided.

Abstract: The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.

Abstract: Selective anthranilamide pyridinamides as VEGFR-2 and VEGFR-3 inhibitors, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.

Abstract: The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.

Abstract: In a method for correlative estimation of a mobile radio channel on the basis of a training sequence (TS) which is transmitted via the mobile radio channel, a sequence of P received symbols is correlated with a subsequence of length P of the training sequence, in order to calculate a first estimated channel coefficient (ĥ0(1)). Furthermore, the same sequence of P received symbols is correlated with at least some of the subsequences of the training sequence (TS) shifted through ±1, ±2, . . . , ±(Lt−1) symbol positions, in order to calculate a number of further estimated channel coefficients (ĥ±1(1),ĥ±2(1), . . . ,ĥ±(Lt−1)(1)).

Abstract: A method of identifying a compound that modulates the activity of a cellular regulator is provided. The method consists of contacting a sample containing a cellular regulator and a nucleic acid element acted on by the cellular regulator with a test compound under conditions that allow replication or expression of the nucleic acid element or a gene or mRNA operatively linked to the nucleic acid element or gene, and an increase or decrease in the amount of replication or expression in the presence of the test compound compared to the absence of the test compound indicates that the compound has cellular regulator modulatory activity. A method of treating a HCV infection is also provided.

Abstract: 1

Abstract: A process for the production of 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones, especially 4-(4-pyridylmethyl)-1(2H)-phthalazinone, is described, which is characterized by the reaction of phthalidyl-3-triphenylphosphonium salt with 4-pyridine aldehyde in the presence of a basic adjuvant, subsequent reaction with hydrazine hydrate and subsequent acid treatment, whereby this process avoids the technical safety and environmental problems of the known processes.

Abstract: The invention relates to 3,5-diamino-1,2,4-triazoles as kinase inhibitors, the production thereof and the use of the same as a medicament for treating cancer, for example solid tumours and leukaemia, auto-immune diseases such as psoriasis, alopecia and multiple sclerosis, alopecia induced by chemotherapeutic agents and mucositis, cardiovascular diseases such as stenoses, arterioscleroses, and restenoses, infectious diseases such as those caused by unicellular parasites such as trypanosome, toxoplasma or plasmodium, or by fungi, nephrological diseases such as glomerulonephritis, chronic neurodegenerative diseases such as Huntington's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease, acute neurodegenerative diseases such as cerebral ischemia and neurotrauma, and viral infections such as cytomegalovirus infections, herpes, hepatitis B and C, and HIV diseases.

Abstract: Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production, as well as intermediate products for their production, and the use as pharmaceutical agents for treating various diseases are described.

Abstract: In a device and method for detecting bad or unreliable frames in a radio receiver the threshold values for the number of errors or metric are adapted in dependence on the type of transmission channel. For slowly varying transmission channels, a higher quality is demanded than for rapidly varying transmission channels. The type of transmission channel currently present can be deduced by means of the proportion of data packets having the metric zero.

Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.

Abstract: In a method to compensate for a step DC disturbance (1) in a baseband signal in a homodyne radio receiver, the time profile of the step DC disturbance within a burst is determined. In order to produce a step-corrected baseband signal, the determined time profile (2) is then calculated from the digitized baseband signal.